STOCK TITAN

Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023.

Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update.

Earnings Call and Webcast Details:

The webcast of the earnings call will be live at: Link Directly to Webcast

To attend by telephone, please use the information below for dial-in access.

  • Date and Time: May 8, 2023 – 8:30 a.m. Eastern Time
  • Please register for the call. You can register any time starting now through the call.
  • Link to register: Registration Link
  • Registration in advance is encouraged.   As part of the registration process, you can choose to be provided with the dial-in and PIN or to use the automated “Call Me” feature.

Please visit the Investor Relations website at ir.conformis.com on May 8, 2023, to view the earnings release prior to the webcast and conference call.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.
Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future press releases via e-mail alerts, sign up at ir.conformis.com.

Contact
Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598 


Conformis Inc.

NASDAQ:CFMS

CFMS Rankings

CFMS Latest News

CFMS Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing

About CFMS

our mission patients vary in more ways than gender, race, and size. at conformis, we believe that optimizing implant fit and performance requires a patient-specific approach. our mission is to provide best-in-class, patient-specific implants and instrumentation that offer unique advantages over traditional orthopedic implants. we start with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. our implants are individually sized and shaped to fit to each patient’s unique anatomy, providing precise anatomic fit and preserving healthy tissue. our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. by combining our personalized implants with our unique instrumentation, a surgeon is able to provide a custom solution that preserves more of a patient’s joint and minimizes surgical trauma. our company conformis, inc. is a privately h